| circCPA4 induces malignant behaviors of prostate cancer via miR-491-5p/SHOC2 feedback loop. | circCPA4 induces malignant behaviors of prostate cancer via miR-491-5p/SHOC2 feedback loop.
Xu W, Zhong Z, Gu L, Xiao Y, Chen B, Hu W., Free PMC Article | 02/5/2024 |
| Aberrant N-myristoylation as a prelude to autoimmune manifestations in patients with SHOC2 mutations. | Aberrant N-myristoylation as a prelude to autoimmune manifestations in patients with SHOC2 mutations.
Rigante D, Leoni C, Onesimo R, Giorgio V, Trevisan V, Zampino G. | 11/7/2023 |
| SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus. | SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus.
Geng W, Cao M, Dong K, An J, Gao H., Free PMC Article | 06/2/2023 |
| LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis. | LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis.
Du H, Hou S, Zhang L, Liu C, Yu T, Zhang W., Free PMC Article | 05/30/2023 |
| lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis. | lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis.
Shi C, Ren S, Zhao X, Li Q. | 12/10/2022 |
| Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome. | Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.
Bonsor DA, Alexander P, Snead K, Hartig N, Drew M, Messing S, Finci LI, Nissley DV, McCormick F, Esposito D, Rodriguez-Viciana P, Stephen AG, Simanshu DK., Free PMC Article | 10/22/2022 |
| Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex. | Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.
Kwon JJ, Hajian B, Bian Y, Young LC, Amor AJ, Fuller JR, Fraley CV, Sykes AM, So J, Pan J, Baker L, Lee SJ, Wheeler DB, Mayhew DL, Persky NS, Yang X, Root DE, Barsotti AM, Stamford AW, Perry CK, Burgin A, McCormick F, Lemke CT, Hahn WC, Aguirre AJ., Free PMC Article | 10/1/2022 |
| Structure of the MRAS-SHOC2-PP1C phosphatase complex. | Structure of the MRAS-SHOC2-PP1C phosphatase complex.
Hauseman ZJ, Fodor M, Dhembi A, Viscomi J, Egli D, Bleu M, Katz S, Park E, Jang DM, Porter KA, Meili F, Guo H, Kerr G, Mollé S, Velez-Vega C, Beyer KS, Galli GG, Maira SM, Stams T, Clark K, Eck MJ, Tordella L, Thoma CR, King DA., Free PMC Article | 10/1/2022 |
| Structural basis for SHOC2 modulation of RAS signalling. | Structural basis for SHOC2 modulation of RAS signalling.
Liau NPD, Johnson MC, Izadi S, Gerosa L, Hammel M, Bruning JM, Wendorff TJ, Phung W, Hymowitz SG, Sudhamsu J., Free PMC Article | 09/17/2022 |
| Expanding the molecular spectrum of pathogenic SHOC2 variants underlying Mazzanti syndrome. | Expanding the molecular spectrum of pathogenic SHOC2 variants underlying Mazzanti syndrome.
Motta M, Solman M, Bonnard AA, Kuechler A, Pantaleoni F, Priolo M, Chandramouli B, Coppola S, Pizzi S, Zara E, Ferilli M, Kayserili H, Onesimo R, Leoni C, Brinkmann J, Vial Y, Kamphausen SB, Thomas-Teinturier C, Guimier A, Cordeddu V, Mazzanti L, Zampino G, Chillemi G, Zenker M, Cavé H, den Hertog J, Tartaglia M., Free PMC Article | 09/3/2022 |
| The Clinical and Molecular Assessment of Iranian Families with Severe Congenital Neutropenia, Identification of HYOU1 and SHOC2 as Potential Novel Gene Defects. | The Clinical and Molecular Assessment of Iranian Families with Severe Congenital Neutropenia, Identification of HYOU1 and SHOC2 as Potential Novel Gene Defects.
Arab F, Rezaei N, Taheri F, Kouhpeikar H, Rayzan E, Mirbeyk M, Zare-Abdollahi D, Ghadami M. | 07/23/2022 |
| Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy. | Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy.
Motta M, Sagi-Dain L, Krumbach OHF, Hahn A, Peleg A, German A, Lissewski C, Coppola S, Pantaleoni F, Kocherscheid L, Altmüller F, Schanze D, Logeswaran T, Chahrokh-Zadeh S, Munzig A, Nakhaei-Rad S, Cavé H, Ahmadian MR, Tartaglia M, Zenker M. | 08/14/2021 |
| The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease. | The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease.
Jang H, Stevens P, Gao T, Galperin E., Free PMC Article | 07/31/2021 |
| SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer. | SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer.
Geng W, Dong K, Pu Q, Lv Y, Gao H., Free PMC Article | 10/10/2020 |
| Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. | Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ., Free PMC Article | 09/19/2020 |
| miR-299-3p was significantly downregulated in thyroid cancer (TC) tissues and cell lines. miR-299-3p could inhibit cell proliferation and cell cycle progression, whereas remarkably promote cell apoptosis in TC cell lines. Bioinformatics predicted that SHOC2 might be a potential target of miR-299-3p. Subsequent Dual-Luciferase reporter analysis validated this hypothesis. | MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2.
Chen X, Qi M, Yang Q, Li JY. | 06/20/2020 |
| Shoc2 single-domain antibodies can be used to understand functional mechanisms governing complex multiprotein signaling modules. | Single-domain antibodies for functional targeting of the signaling scaffold Shoc2.
Jang H, Wilson PG, Sau M, Chawla U, Rodgers DW, Galperin E., Free PMC Article | 04/11/2020 |
| study highlights a context-dependent contribution of SHOC2 to ERK pathway dynamics that is preferentially engaged by KRAS oncogenic signaling | SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
Boned Del Río I, Young LC, Sari S, Jones GG, Ringham-Terry B, Hartig N, Rejnowicz E, Lei W, Bhamra A, Surinova S, Rodriguez-Viciana P., Free PMC Article | 04/11/2020 |
| Study reports the identification of a novel RASopathy-causing SHOC2 mutation associated with prenatal-onset hypertrophic cardiomyopathy. This variant results in enhanced MRAS and PPP1CB binding and increased MAPK activation, but does not drive constitutive translocation of SHOC2 to the plasma membrane. | Clinical and functional characterization of a novel RASopathy-causing SHOC2 mutation associated with prenatal-onset hypertrophic cardiomyopathy.
Motta M, Giancotti A, Mastromoro G, Chandramouli B, Pinna V, Pantaleoni F, Di Giosaffatte N, Petrini S, Mazza T, D'Ambrosio V, Versacci P, Ventriglia F, Chillemi G, Pizzuti A, Tartaglia M, De Luca A. | 04/4/2020 |
| in fibroblasts from patients with inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) that harbor germline mutations in VCP, the levels of Shoc2 ubiquitination and ERK1/2 phosphorylation are imbalanced. | VCP/p97 controls signals of the ERK1/2 pathway transmitted via the Shoc2 scaffolding complex: novel insights into IBMPFD pathology.
Jang H, Jang ER, Wilson PG, Anderson D, Galperin E., Free PMC Article | 01/11/2020 |
| we unraveled the anti-Colorectal cancer (CRC) function of Celastrol and confirmed for the first time that it inhibited the ERK1/2 pathway through binding to Shoc2 | Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol.
Xiao-Pei H, Ji-Kuai C, Xue W, Dong YF, Yan L, Xiao-Fang Z, Ya-Min P, Wen-Jun C, Jiang-Bo Z., Free PMC Article | 07/20/2019 |
| SHOC2 mutation is associated with Systemic lupus erythematosus. | Systemic lupus erythematosus in a patient with Noonan syndrome-like disorder with loose anagen hair 1: More than a chance association.
Uehara T, Hosogaya N, Matsuo N, Kosaki K. | 05/25/2019 |
| Overexpression or knockdown of Sur8 increases or decreases, respectively, the proliferation or transformation of colorectal cancer (CRC) cell lines. Sur8 knockdown attenuates the migration and invasion of HCT116 CRC cells. | Sur8 mediates tumorigenesis and metastasis in colorectal cancer.
Lee YM, Kaduwal S, Lee KH, Park JC, Jeong WJ, Choi KY., Free PMC Article | 12/16/2017 |
| Results provide evidence that SHOC2 trapping at different subcellular sites has a diverse impact on ERK signaling strength and dynamics, suggesting a dual counteracting modulatory role of SHOC2 in the control of ERK signaling exerted at different intracellular compartments. | SHOC2 subcellular shuttling requires the KEKE motif-rich region and N-terminal leucine-rich repeat domain and impacts on ERK signalling.
Motta M, Chillemi G, Fodale V, Cecchetti S, Coppola S, Stipo S, Cordeddu V, Macioce P, Gelb BD, Tartaglia M. | 08/26/2017 |
| results demonstrate that PSMC5 is a new and important player involved in regulating ERK1/2 signal transmission through the remodeling of Shoc2 scaffold complex in a spatially-defined manner. | Spatial control of Shoc2-scaffold-mediated ERK1/2 signaling requires remodeling activity of the ATPase PSMC5.
Jang ER, Jang H, Shi P, Popa G, Jeoung M, Galperin E., Free PMC Article | 09/10/2016 |